<DOC>
	<DOCNO>NCT00657007</DOCNO>
	<brief_summary>The purpose thie study evaluate safety , tolerability , immunogenicity , pharmacokinetics pharmacodynamics belimumab ( LymphoStat-B™ ) subject SLE .</brief_summary>
	<brief_title>Phase 1 Study Belimumab Subjects With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Key Clinical diagnosis SLE ACR criterion Stable SLE disease activity On stable SLE treatment regimen History measurable autoantibody Key Pregnant nursing Received nonFDA approve investigational agent within last 28 day Received cyclosporin , intravenous immunoglobulin ( IVIG ) plasmapheresis within last 6 month Active lupus nephritis require hemodialysis , intravenous cyclophosphamide ( Cytoxan™ ) , highdose prednisone ( &gt; 100 mg/day ) within last 6 month Active central nervous system ( CNS ) lupus require medical intervention within last 6 month History renal transplant History clinical evidence active significant acute chronic disease Have require management hospitalization infection within last 4 week . History hypogammaglobulinemia IgA deficiency Have current drug alcohol addiction History test positive screening HIV , Hepatitis B Hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>lupus</keyword>
	<keyword>SLE</keyword>
</DOC>